Alzheimer's disease (AD) is the most common cause of dementia worldwide, and its
prevalence is rapidly increasing due to extended lifespans. Among the increasing number of …

Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …

Late-onset Alzheimer's disease is a prevalent age-related polygenic disease that accounts
for 50–70% of dementia cases. Currently, only a fraction of the genetic variants underlying …

Pathological hallmarks of Alzheimer's disease (AD) precede clinical symptoms by years,
indicating a period of cognitive resilience before the onset of dementia. Here, we report that …

Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …

Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …

There is poor knowledge about the clinical effects of Lewy body (LB) pathology in patients
with cognitive impairment, especially when coexisting with Alzheimer's disease (AD) …

Microglia activation is observed in various neurodegenerative diseases. Recent advances in
single-cell technologies have revealed that these reactive microglia were with high spatial …

Aggregation of specific proteins are histopathological hallmarks of several
neurodegenerative diseases, such as, Amyloid β (Aβ) plaques and tau neurofibrillary …

Nearly half a century has passed since the discovery of cytoplasmic inheritance of human
chloramphenicol resistance. The inheritance was then revealed to take place maternally by …